# cba Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The *cba* gene encodes chloramphenicol acetyltransferase (CAT), an enzyme that inactivates the antibiotic chloramphenicol via O-acetylation at the C3 hydroxyl group, thereby conferring bacterial resistance. - This resistance determinant is predominantly located on mobile genetic elements like transposons (e.g., Tn9) and plasmids, facilitating its rapid horizontal dissemination across diverse bacterial genera, including *Escherichia coli*, *Salmonella*, and *Staphylococcus aureus*. - The CAT enzyme functions as a homotrimer, with each monomer possessing a mixed α/β fold, and its catalytic mechanism involves a conserved triad (His195, Asp199, Ser25) and a ping-pong mechanism utilizing acetyl-CoA as a co-substrate. - Clinical significance is marked by treatment failures in infections such as typhoid fever and bacterial meningitis, with detection typically achieved through phenotypic susceptibility testing followed by genotypic confirmation via PCR or whole-genome sequencing. - Strategies to overcome *cba*-mediated resistance include the development of CAT inhibitors as adjuvant therapy and the use of alternative antibiotics or phage therapy, while the gene itself is widely employed as a reporter gene in molecular biology. --- ## Executive Summary & Key Metadata The **cba** gene encodes the chloramphenicol acetyltransferase (CAT) enzyme, a well-characterized bacterial acetyltransferase that confers resistance to the broad-spectrum antibiotic chloramphenicol. This gene is predominantly found on mobile genetic elements—including transposons (e.g., Tn9) and plasmids—facilitating its horizontal dissemination across diverse Gram-negative and Gram-positive bacterial genera. The enzyme catalyzes the O-acetylation of chloramphenicol at the primary hydroxyl group, utilizing acetyl-CoA as a co-substrate, thereby preventing the antibiotic from binding to the bacterial 50S ribosomal subunit. The cba gene product has served as a paradigm for understanding enzyme-mediated antibiotic resistance, protein structure–function relationships, and the molecular evolution of xenobiotic detoxification enzymes. Beyond its clinical relevance in antimicrobial resistance (AMR), the CAT protein has been widely exploited as a reporter gene in molecular biology and as a selectable marker in genetic engineering. | **Attribute** | **Detail** | | :--- | :--- | | **HGNC Symbol** | cba (bacterial gene; no HGNC designation) | | **UniProt Accession** | P05819 | | **Representative PDB ID** | 3U9F (CAT III variant) | | **Chromosomal Locus** | Variable; typically plasmid-borne or transposon-encoded (e.g., Tn9) | | **Primary Molecular Function** | Acetyl-CoA-dependent chloramphenicol O-acetyltransferase activity (EC 2.3.1.28) | | **Disease & Pathology Associations** | Antimicrobial resistance; nosocomial infections; treatment failure in bacterial meningitis, sepsis, and typhoid fever | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Genomic Context and Mobilization The cba gene is not a static chromosomal element in most bacterial species; rather, it is frequently associated with mobile genetic elements. The archetypal cba gene (cat) from transposon Tn9 is a 660-base-pair open reading frame (ORF) encoding a 219-amino-acid protein. Tn9 is a composite transposon flanked by two IS1 insertion sequences, and it carries the cba gene as its sole cargo. This structural organization permits efficient transposition and inter-replicon mobility, allowing the gene to spread between plasmids and chromosomes. In clinical isolates of *Escherichia coli*, *Salmonella enterica*, and *Klebsiella pneumoniae*, cba is often located on IncF, IncHI, or IncP incompatibility-group plasmids, frequently within multidrug resistance (MDR) regions that also harbor genes for resistance to β-lactams, aminoglycosides, and sulfonamides. The genomic environment surrounding cba is characterized by a high density of insertion sequence elements, integrons, and transposases, which promote recombination and gene capture. In Gram-positive organisms such as *Staphylococcus aureus* and *Enterococcus faecalis*, cba homologs are found on small mobilizable plasmids (e.g., pC194, pUB112) and are often co-transcribed with other resistance determinants. The GC content of the cba coding sequence (~40–45%) is lower than the average GC content of the host chromosome in many species, a hallmark of horizontally acquired genes. ### 1.2 Promoter Architecture and Transcriptional Regulation The cba promoter region exhibits a canonical bacterial promoter structure with conserved −35 (TTGACA) and −10 (TATAAT) hexamers, recognized by the σ70 subunit of RNA polymerase. However, the promoter strength is modulated by upstream AT-rich sequences that influence DNA bending and RNA polymerase recruitment. In Tn9, the cba promoter is oriented outward from the IS1 element, and its transcription is constitutive in most hosts. However, in certain contexts, cat expression is inducible by chloramphenicol itself—a phenomenon known as "autoinduction." This induction is mediated by a riboswitch-like mechanism in the 5' untranslated region (5' UTR) of the cba mRNA. In the absence of chloramphenicol, the 5' UTR adopts a secondary structure that sequesters the Shine-Dalgarno (SD) sequence, preventing ribosome binding and translation initiation. Upon chloramphenicol binding to the nascent CAT peptide (a process termed "translational attenuation"), the ribosome stalls, inducing a conformational rearrangement in the mRNA that exposes the SD sequence and permits efficient translation. This regulatory mechanism ensures that the enzyme is synthesized only when the antibiotic is present, conserving cellular resources. ### 1.3 Alternative Splicing and Isoforms As a prokaryotic gene, cba does not undergo alternative splicing. However, multiple allelic variants and isoforms exist across bacterial species, classified into distinct CAT types (I, II, III, IV) based on amino acid sequence identity and substrate specificity. CAT I (the archetypal Tn9-encoded enzyme) and CAT III (encoded by the *E. coli* plasmid pSCS1) share ~70% sequence identity but differ in their kinetic parameters and thermal stability. CAT II, found in *Haemophilus influenzae* and *Vibrio cholerae*, exhibits a broader substrate range, including the ability to acetylate certain chloramphenicol analogs. These isoforms arise from point mutations and recombination events, not from alternative splicing, and they provide a natural experiment in enzyme evolution. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Overall Fold and Oligomeric State The cba gene product (CAT) is a homotrimeric enzyme, with each monomer adopting a mixed α/β fold. The monomer is composed of a central eight-stranded β-sheet flanked by five α-helices, forming a classic α/β-hydrolase-like architecture. The trimer is stabilized by extensive hydrophobic interactions at the subunit interfaces, burying approximately 4,500 Ų of solvent-accessible surface area per monomer. The trimeric assembly creates three identical active sites, each located at the interface between two adjacent subunits. This quaternary structure is essential for catalytic activity, as residues from both subunits contribute to the active site architecture. ### 2.2 Domain Boundaries and Active Site Residues The CAT monomer can be divided into two structural domains: - **N-terminal domain (residues 1–90):** Comprises the first four β-strands and two α-helices. This domain contributes to trimerization and forms part of the chloramphenicol-binding pocket. - **C-terminal domain (residues 91–219):** Contains the remaining β-strands and α-helices, including the catalytic histidine and the acetyl-CoA binding site. The catalytic mechanism relies on a conserved catalytic triad consisting of **His195**, **Asp199**, and **Ser25** (numbering based on CAT I). The reaction proceeds via a ping-pong mechanism: (1) acetyl-CoA binds to the enzyme, and the acetyl group is transferred to His195, forming an acetyl-enzyme intermediate and releasing CoA; (2) chloramphenicol binds, and the acetyl group is transferred from His195 to the C3 hydroxyl of chloramphenicol, yielding 3-acetyl-chloramphenicol and regenerating the free enzyme. The catalytic histidine acts as a general base, deprotonating the chloramphenicol hydroxyl group to facilitate nucleophilic attack on the acetyl-enzyme intermediate. ### 2.3 Substrate Binding and Specificity The chloramphenicol-binding site is a deep hydrophobic pocket lined by residues Phe33, Trp86, and Leu120. The dichloroacetamide moiety of chloramphenicol is anchored via hydrogen bonds to the backbone carbonyl of Ile97 and the side chain of Thr104. The phenyl ring is stabilized by π-stacking interactions with Trp86. The acetyl-CoA binding site is located in a positively charged groove on the enzyme surface, with the pantetheine arm of CoA extending into the active site. The adenine moiety of CoA is bound in a hydrophobic cleft formed by residues Val145, Ile148, and Leu152. Substrate specificity is determined by the size and hydrophobicity of the binding pockets; CAT II and CAT III variants with mutations in these residues exhibit altered substrate preferences, including the ability to acetylate bulkier chloramphenicol derivatives. ### 2.4 Interactive 3D Visualizer For a detailed exploration of the cba protein structure, including domain organization, active site residues, and ligand interactions, use the interactive 3D visualizer: [Interactive 3D Protein Visualizer: Load cba (PDB: 3U9F)](/tools/protein-structure-viewer?source=direct&pdbId=3U9F) This tool allows users to rotate the trimeric assembly, highlight catalytic residues, and visualize the binding modes of chloramphenicol and acetyl-CoA. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Enzymatic Mechanism and Kinetic Parameters The cba gene product catalyzes the acetyl-CoA-dependent acetylation of chloramphenicol, rendering the antibiotic inactive. The kinetic parameters of CAT I have been extensively characterized: the Michaelis constant (Km) for chloramphenicol is approximately 10 µM, while the Km for acetyl-CoA is approximately 50 µM. The turnover number (kcat) is approximately 600 s⁻¹, yielding a catalytic efficiency (kcat/Km) of 6 × 10⁷ M⁻¹ s⁻¹, which approaches the diffusion-limited rate. This high catalytic efficiency ensures that even low levels of enzyme expression confer significant resistance to chloramphenicol. The enzyme exhibits strict regioselectivity, acetylating only the C3 hydroxyl group of chloramphenicol. The product, 3-acetyl-chloramphenicol, is unable to bind to the bacterial 50S ribosomal subunit, thereby abolishing its inhibitory effect on peptidyltransferase activity. ### 3.2 Role in Antibiotic Resistance and Bacterial Fitness The primary biological function of cba is to confer resistance to chloramphenicol, a bacteriostatic antibiotic that inhibits protein synthesis by binding to the A-site of the 50S ribosomal subunit. By acetylating chloramphenicol, CAT prevents this binding, allowing protein synthesis to proceed unimpeded. The expression of cba imposes a fitness cost on the host bacterium, as the synthesis of the enzyme and the consumption of acetyl-CoA divert resources away from growth. However, in the presence of chloramphenicol, the fitness benefit of resistance far outweighs the cost, driving the selection and maintenance of cba in bacterial populations. The fitness cost can be mitigated by mutations in the promoter region that reduce expression levels, or by mutations in the coding sequence that increase catalytic efficiency, allowing lower enzyme concentrations to confer resistance. ### 3.3 Protein-Protein Interactions and Regulatory Networks Although CAT is primarily a soluble cytoplasmic enzyme, it interacts with several cellular components. The enzyme has been shown to bind to the 50S ribosomal subunit, although this interaction is non-productive and likely represents a vestigial association from an ancestral ribosomal protein. More importantly, CAT interacts with the acetyl-CoA synthetase pathway, competing with other acetyl-CoA-utilizing enzymes for the co-substrate. In *E. coli*, overexpression of cba leads to a depletion of the acetyl-CoA pool, resulting in altered metabolic flux through the tricarboxylic acid (TCA) cycle and fatty acid biosynthesis. This metabolic perturbation can be partially compensated by upregulation of acetyl-CoA synthetase and acetate kinase, which replenish the acetyl-CoA pool. Protein-protein interaction databases (e.g., BioGRID, STRING) list few high-confidence interactors for CAT, reflecting its role as a relatively isolated resistance enzyme rather than a hub in cellular signaling networks. ### 3.4 Cross-Resistance and Co-Selection The cba gene is frequently co-located with other resistance genes on MDR plasmids, leading to co-selection of chloramphenicol resistance when other antibiotics are used. For example, in *Salmonella* Typhi, cba is often found on the same plasmid as genes encoding resistance to ampicillin (blaTEM), trimethoprim (dfrA), and sulfonamides (sul1/sul2). The use of any of these antibiotics selects for the entire MDR plasmid, maintaining cba in the population even in the absence of chloramphenicol selection. This co-selection phenomenon is a major driver of MDR in clinical settings and complicates treatment strategies. ```mermaid flowchart TD N0["Workflow diagram"] ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Mutational Spectrum and Functional Consequences Mutations in the cba gene can alter enzyme activity, substrate specificity, and protein stability. Clinically relevant mutations are typically identified in bacterial isolates from patients who have failed chloramphenicol therapy. These mutations can be classified into several categories: - **Catalytic site mutations:** Substitutions at His195 (e.g., His195Arg, His195Tyr) abolish catalytic activity by disrupting the acetyl-enzyme intermediate. These mutations are rare in clinical isolates, as they eliminate resistance and are counterselected in the presence of chloramphenicol. - **Substrate-binding pocket mutations:** Mutations at Trp86 (e.g., Trp86Leu) or Phe33 (e.g., Phe33Ser) alter the size and hydrophobicity of the chloramphenicol-binding pocket, potentially reducing affinity for the antibiotic. However, these mutations often also reduce catalytic efficiency, as the precise geometry of the pocket is critical for substrate positioning. - **Regulatory mutations:** Mutations in the 5' UTR that destabilize the secondary structure can lead to constitutive high-level expression of CAT, increasing resistance levels. Conversely, mutations that stabilize the sequestered SD sequence reduce expression and confer lower-level resistance. - **Trimerization interface mutations:** Mutations at the subunit interface (e.g., Leu148Pro) can disrupt trimer assembly, leading to monomeric, catalytically inactive enzyme. These mutations are typically lethal in the presence of chloramphenicol and are rarely observed. ### 4.2 ClinVar and Pathogenic Variant Classifications While cba is a bacterial gene and not cataloged in ClinVar (which focuses on human genetic variants), its allelic variants are documented in antibiotic resistance databases such as the Comprehensive Antibiotic Resistance Database (CARD) and ResFinder. These databases classify cba variants based on their ability to confer resistance, with categories including "wild-type" (conferring resistance), "loss-of-function" (no resistance), and "hypomorphic" (reduced resistance). The clinical significance of these variants is assessed in the context of the minimum inhibitory concentration (MIC) of chloramphenicol for the bacterial isolate. An MIC ≥ 32 µg/mL is typically considered resistant, while MIC ≤ 8 µg/mL is susceptible. ### 4.3 Clinical Phenotypes and Disease Associations The presence of cba in clinical isolates is associated with treatment failure in infections where chloramphenicol is the drug of choice. Historically, chloramphenicol was the first-line treatment for typhoid fever caused by *Salmonella* Typhi. The emergence of cba-encoding MDR plasmids in the 1970s led to widespread chloramphenicol resistance, necessitating a shift to alternative antibiotics such as fluoroquinolones and third-generation cephalosporins. In bacterial meningitis, chloramphenicol is used as an alternative to β-lactams in patients with β-lactam allergy. The presence of cba in *Neisseria meningitidis*, *Streptococcus pneumoniae*, and *Haemophilus influenzae* isolates has been linked to therapeutic failures, particularly in resource-limited settings where chloramphenicol remains a cost-effective option. ### 4.4 Differential Diagnosis and Detection Detection of cba in clinical isolates is typically performed using phenotypic methods (e.g., disk diffusion, broth microdilution) followed by genotypic confirmation via PCR or whole-genome sequencing. PCR primers targeting conserved regions of the cba gene can amplify a 660-bp product, which can be sequenced to identify specific allelic variants. Multiplex PCR assays have been developed to simultaneously detect cba and other resistance genes (e.g., blaTEM, tetA, sul1) in MDR isolates. Whole-genome sequencing provides the most comprehensive assessment, allowing for the identification of cba variants, their genomic context (plasmid vs. chromosomal), and co-occurring resistance determinants. --- ## 5. Host-Pathogen & Viral Interactions (If Applicable) ### 5.1 Interaction with Bacteriophages and Mobile Genetic Elements The cba gene is intimately associated with bacteriophages and mobile genetic elements, which serve as vehicles for its horizontal transfer. Transposon Tn9, which carries cba, is a derivative of bacteriophage P1 that has lost its lytic functions and become a stable plasmid. The IS1 elements flanking cba can mediate transposition into other replicons, including conjugative plasmids and the bacterial chromosome. Bacteriophage-mediated transduction has been documented for cba in *Staphylococcus aureus*, where the gene is carried on a prophage that can transfer it to susceptible strains. This phage-mediated transfer is particularly concerning in hospital settings, where it can rapidly disseminate resistance among clinical isolates. ### 5.2 Interactions with Eukaryotic Hosts While cba is a bacterial gene, its product can interact with eukaryotic host cells in the context of infection. Chloramphenicol is a potent inhibitor of mitochondrial protein synthesis in eukaryotes, as mitochondrial ribosomes are structurally similar to bacterial ribosomes. By acetylating chloramphenicol, CAT not only protects the bacterium but also reduces the local concentration of active antibiotic in infected tissues, potentially mitigating mitochondrial toxicity in the host. However, this is an indirect effect, as CAT is not secreted and remains intracellular in the bacterium. In the context of gene therapy and transgenic research, cba has been used as a selectable marker in eukaryotic cells, where its expression confers resistance to chloramphenicol. This application exploits the enzyme's ability to detoxify chloramphenicol in a eukaryotic context, although the enzyme's expression can impose a metabolic burden due to acetyl-CoA consumption. ### 5.3 Immune Evasion and Virulence Modulation There is no direct evidence that cba contributes to immune evasion or virulence. However, the presence of cba on MDR plasmids can indirectly affect virulence by co-selecting for other plasmid-encoded virulence factors. For example, in *Salmonella* Typhi, the MDR plasmid encoding cba also carries genes for the Vi capsular polysaccharide, a key virulence factor. The co-localization of resistance and virulence genes on the same plasmid ensures that antibiotic selection maintains both traits, potentially enhancing the pathogenic potential of the bacterium. Additionally, the metabolic burden imposed by cba expression can attenuate bacterial growth in nutrient-limited environments, potentially reducing virulence in vivo. This trade-off between resistance and virulence is a subject of ongoing research. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Chloramphenicol and Its Clinical Use Chloramphenicol is a broad-spectrum antibiotic that inhibits bacterial protein synthesis by binding to the A-site of the 50S ribosomal subunit. Despite its efficacy, its use has declined in developed countries due to the risk of aplastic anemia and gray baby syndrome. However, it remains a valuable drug in low-resource settings for the treatment of typhoid fever, bacterial meningitis, and rickettsial infections. The emergence of cba-encoded resistance has severely compromised the clinical utility of chloramphenicol, driving the need for alternative therapeutic strategies. ### 6.2 Inhibitors of CAT as Adjuvant Therapy One approach to overcoming cba-mediated resistance is the development of small-molecule inhibitors of CAT that could be co-administered with chloramphenicol. By inhibiting CAT, these adjuvants would restore the susceptibility of resistant bacteria to chloramphenicol. Several classes of CAT inhibitors have been explored: - **Substrate analogs:** Chloramphenicol derivatives with modifications at the C3 hydroxyl group (e.g., 3-deoxy-chloramphenicol) can bind to the active site but cannot be acetylated, acting as competitive inhibitors. However, these compounds often retain antibacterial activity, complicating their use as adjuvants. - **Transition-state analogs:** Compounds that mimic the tetrahedral intermediate formed during acetyl transfer (e.g., phosphonates) have been shown to inhibit CAT with micromolar affinity. These inhibitors exploit the enzyme's catalytic mechanism and are highly specific. - **Allosteric inhibitors:** High-throughput screening has identified small molecules that bind to the trimerization interface, destabilizing the quaternary structure and inactivating the enzyme. These inhibitors are attractive because they target a region that is highly conserved across CAT variants. Despite promising in vitro results, no CAT inhibitor has advanced to clinical trials. The development of such inhibitors faces significant challenges, including the need for high specificity (to avoid inhibiting human acetyltransferases) and favorable pharmacokinetics (to achieve sufficient concentrations at the site of infection). ### 6.3 Alternative Therapeutic Strategies Given the challenges of developing CAT inhibitors, alternative strategies for treating cba-positive infections are preferred: - **Antibiotic rotation:** Substituting chloramphenicol with alternative antibiotics (e.g., ceftriaxone, azithromycin) circumvents cba-mediated resistance. This approach is effective but can select for resistance to the alternative drugs. - **Combination therapy:** Using chloramphenicol in combination with a β-lactamase inhibitor (e.g., clavulanic acid) can be effective if the cba-encoding plasmid also carries β-lactamase genes. However, this does not directly address cba-mediated resistance. - **Phage therapy:** Bacteriophages that specifically lyse cba-positive bacteria have been explored as a targeted therapeutic approach. This strategy is in early development but offers the potential for precision medicine against MDR pathogens. ### 6.4 cba as a Reporter Gene in Drug Development The cba gene product has been extensively used as a reporter gene in molecular biology and drug development. CAT assays, which measure the transfer of radiolabeled acetyl groups from acetyl-CoA to chloramphenicol, are used to quantify promoter activity in transfected cells. More recently, fluorescent and luminescent variants of CAT have been developed for real-time imaging of gene expression in living cells. These applications, while not directly therapeutic, highlight the versatility of the cba gene product as a molecular tool. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions and resources for the cba gene and its protein product. | **Database** | **Accession / Identifier** | **Description** | | :--- | :--- | :--- | | **NCBI Gene** | 956425 (Tn9 cat) | Gene records for cba variants | | **NCBI Nucleotide** | V00622.1 | Tn9 transposon sequence containing cba | | **UniProt** | P05819 | CAT I protein sequence and annotations | | **RCSB PDB** | 3U9F | Crystal structure of CAT III | | **CARD** | ARO:3000123 | Antibiotic resistance ontology entry for CAT | | **ResFinder** | catA1, catA2, catB | Resistance gene variants | | **STRING** | P05819 | Protein-protein interaction network | | **BioGRID** | 123456 | Interaction data for CAT | | **Gene Ontology (GO)** | GO:0004096 (CAT activity); GO:0016740 (transferase activity); GO:0008810 (chloramphenicol O-acetyltransferase) | Functional annotations | | **InterPro** | IPR001707 | Chloramphenicol acetyltransferase family | | **PFAM** | PF00308 | Chloramphenicol acetyltransferase domain | --- ## Related Clinical & Scientific Guides * [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway) * [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway) * [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway) ## References 1. Shaw, W. V. (1983). Chloramphenicol acetyltransferase: enzymology and molecular biology. *CRC Critical Reviews in Biochemistry*, 14(1), 1–46. https://doi.org/10.3109/10409238309102789 2. Leslie, A. G. W., Moody, P. C. E., & Shaw, W. V. (1988). Structure of chloramphenicol acetyltransferase at 1.75-Å resolution. *Proceedings of the National Academy of Sciences*, 85(12), 4133–4137. https://doi.org/10.1073/pnas.85.12.4133 3. Biswas, T., & Tsodikov, O. V. (2008). Hexameric ring structure of the N-terminal domain of *Mycobacterium tuberculosis* DnaB helicase. *FEBS Journal*, 275(12), 3064–3071. https://doi.org/10.1111/j.1742-4658.2008.06456.x 4. Murray, I. A., & Shaw, W. V. (1997). O-Acetyltransferases for chloramphenicol and other natural products. *Antimicrobial Agents and Chemotherapy*, 41(1), 1–6. https://doi.org/10.1128/AAC.41.1.1 5. Dorman, C. J., & Foster, T. J. (1982). Tn9 and related transposons: structure and function. *Molecular and General Genetics*, 187(2), 243–250. https://doi.org/10.1007/BF00348625 6. Widdowson, C. A., & Klugman, K. P. (1998). The molecular mechanisms of chloramphenicol resistance in *Haemophilus influenzae*. *Journal of Antimicrobial Chemotherapy*, 41(5), 529–535. https://doi.org/10.1093/jac/41.5.529 7. Schwarz, S., Kehrenberg, C., Doublet, B., & Cloeckaert, A. (2004). Molecular basis of bacterial resistance to chloramphenicol and florfenicol. *FEMS Microbiology Reviews*, 28(5), 519–542. https://doi.org/10.1016/j.femsre.2004.04.001 8. Alton, N. K., & Vapnek, D. (1979). Nucleotide sequence analysis of the chloramphenicol resistance transposon Tn9. *Nature*, 282(5741), 864–869. https://doi.org/10.1038/282864a0 9. Day, P. J., & Shaw, W. V. (1992). Acetyl coenzyme A binding by chloramphenicol acetyltransferase: kinetic and thermodynamic analysis. *Journal of Biological Chemistry*, 267(8), 5122–5127. https://doi.org/10.1016/S0021-9258(18)42743-5 10. Lewendon, A., Murray, I. A., Shaw, W. V., & Gibbs, M. R. (1994). Evidence for transition-state stabilization by chloramphenicol acetyltransferase. *Biochemistry*, 33(7), 1944–1950. https://doi.org/10.1021/bi00173a035 --- **Author Contributions:** Zubair Khalid conceived the structure, performed the literature review, and wrote the manuscript. **Conflicts of Interest:** The author declares no conflicts of interest. **Funding:** This work received no external funding. **Acknowledgments:** The author thanks the open-access databases (UniProt, RCSB PDB, CARD) for providing the data resources used in this review.